Friday, July 10, 2026

pharma · Refractory Focal Onset Epilepsy · Early Parkinson’s Disease

Biohaven Bioscience Ireland

Biohaven Bioscience Ireland clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

GB HQ
EMA registrant Type
Company details
Status
Public
HQ
GB
Programs
7
Drugs
8
Patents
0
Intelligence · Clinical Programs

Biohaven Bioscience Ireland projects

3 ClinicalTrials.gov programs sponsored by Biohaven Bioscience Ireland.

Biohaven Bioscience Ireland has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BHV7000-303

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 3 small molecule active

    1 trial
  2. BHV7000-304

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial
  3. BHV8000-301

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Biohaven Bioscience Ireland have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.